Biological agents may be better sooner, rather than later, in moderate-to-severe Crohn's disease

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.23, Iss.5, 2007-05, pp. : 15-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Teduglutide induces remission in patients with moderate-to-severe Crohn's disease

Inpharma, Vol. 1, Iss. 1541, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Pharmacological treatment in moderate-to-severe Alzheimer's disease

By Hsiung Ging-Yuek Robin Feldman Howard H

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2575-2582

Informa Healthcare

Access to resources Recommend Favorite

Donepezil is better tolerated than rivastigmine in mild-to-moderate Alzheimer's disease

Inpharma, Vol. 1, Iss. 1258, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Memantine: A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer's Disease

By Plosker Greg L. Lyseng-Williamson Katherine A.

PharmacoEconomics, Vol. 23, Iss. 2, 2005-01 ,pp. : 193-206

Adis International

Access to resources Recommend Favorite

Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer’s disease?

By Doggrell Sheila

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 10, 2003-10 ,pp. : 1857-1860

Informa Healthcare

Access to resources Recommend Favorite